According to a recent LinkedIn post from Saluda Medical, the company is drawing attention to long‑term clinical data from its EVOKE Study on closed‑loop spinal cord stimulation (SCS). The post cites results in which 90% of patients who responded at 3 months reportedly remained responders at 36 months, positioning this performance as favorable versus traditional SCS systems.
The LinkedIn post also references a 2024 publication in Reg Anesth Pain Med and reiterates that the Evoke System is indicated for chronic intractable pain of the trunk and/or limbs, with associated safety information. For investors, sustained responder rates over three years may suggest differentiated clinical efficacy that could strengthen Saluda Medical’s competitive position in neuromodulation and support adoption in chronic pain management markets.
If these outcomes translate into broader clinical uptake and reimbursement support, Saluda Medical could see enhanced revenue visibility as closed‑loop technology gains traction among pain specialists. The emphasis on long‑term efficacy may also increase the company’s strategic value relative to other SCS providers, potentially influencing future partnership, commercialization, or exit opportunities in the medtech sector.


